Q-omics provides the consensus-scored MTCO3P22 profile across patient tissues and cancer cell-line models. MTCO3P22 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MTCO3P22 is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, MTCO3P22 RNA expression shows 9,495 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, and ACC as cancer lineages where MTCO3P22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO3P22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO3P22 survival associations across molecular data types. MTCO3P22 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO3P22 RNA expression–survival associations across cancer types. High MTCO3P22 expression shows unfavorable associations in DLBC, but favorable associations in KICH, BLCA, KIRP, THCA and ACC. The KICH Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for MTCO3P22 RNA expression.
This table summarizes MTCO3P22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO3P22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO3P22 shows lower tumor expression in KIRC and KIRP and higher tumor expression in KICH and READ. The KICH box plot shows higher MTCO3P22 RNA expression in tumor versus normal tissue (log2 FC = +0.325, t-test p < 0.001).
This table shows molecular features associated with MTCO3P22 in patient tissues and cancer cell lines. In patient samples, MTCO3P22 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
